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Abstract: The insulin analogs lispro, aspart, and glulisine are the only commercially available 
rapid-acting insulins to treat diabetes. We review the evidence for treating hyperglycemia, using 
insulin, and speciﬁ  cally using rapid-acting analogs in diabetic individuals, on the prevention 
of vascular events. We review the beneﬁ  cial effects of insulin on the vascular system, which 
include vasodilation and anti-inﬂ  ammatory actions. The effects of treating hyperglycemia and 
intensive blood glucose control on vascular outcomes are reviewed.
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Introduction
The epidemic of diabetes is worsening. The Centers for Disease Control estimates that 
over 23 million Americans suffer from diabetes, with an incidence of over 1.4 million 
new cases of diabetes every year.1 As the prevalence of diabetes increases, there 
is greater concern for the vascular complications that accompany diabetes. Insulin 
remains the most potent medication available to treat diabetes, and arguably to prevent 
diabetic complications. Some advocate using insulin much sooner in the course of 
diabetes.2 On the other hand, others believe that insulin may actually be harmful in 
obese type 2 diabetic subjects because it increases body fat, which may exacerbate 
insulin resistance.3,4 This review explores the interplay between insulin and the vas-
cular system with special emphasis on the rapid-acting insulin analogs. Because of 
the heterogeneity of the literature, this paper will refer to vascular events deﬁ  ned very 
loosely, including peripheral events, cardiovascular events, cerebrovascular events, 
and death due to vascular causes.
Is insulin harmful?
The relationship between insulin and vascular events is debatable. One study has 
associated higher serum insulin levels as an independent predictor of cardiovascular 
events. The Helsinki Policeman study was a retrospective study of 22-year mortality 
data of 970 non-diabetic men without coronary artery disease. The authors found an 
increase in cardiovascular mortality among subjects with higher serum insulin levels.5 
A larger study, the Paris Protection Study, followed 7246 non-diabetic men without 
coronary artery disease for an average of 63 months and concluded that higher fasting 
plasma insulin levels were an independent risk factor for the development of coronary 
artery disease.6
Although these studies may suggest that elevated circulating insulin is a direct 
cause of vascular disease, this does not seem to be true. Subjects with insulin produc-
ing neoplasms do not have an increase in clinically overt atherosclerotic disease.7 
This suggests that factors other than hyperinsulinemia are responsible for an increased 
risk of vascular disease. Insulin resistance is often associated with hypertension, lipid 
abnormalities, and obesity, all of which are thought to contribute much more than Vascular Health and Risk Management 2009:5 226
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hyperinsulinemia to the development of vascular disease.8 
In fact, some have proposed that insulin resistance is another 
symptom associated with the metabolic syndrome and cardio-
vascular disease, rather than the root cause of cardiovascular 
disease. Cardiologists performing a population study on 
322 healthy adults have described an “insulin gradient.”9 
These researchers noted a direct correlation between body 
weight and blood pressure and insulin levels. The heavier 
their subjects were, the higher the blood pressure and insulin 
level. Thus, the higher cardiovascular rates seen with higher 
insulin levels may be caused by an increase in other risk fac-
tors such as hypertension, rather than insulin itself.
Such a relationship is often ignored in articles that claim 
an association between insulin resistance and cardiovascular 
events. For example, in the Veteran Affairs-HDL Interven-
tion Trial (VA-HIT), the authors concluded that “the occur-
rence of a new cardiovascular event was dependent on … the 
presence or absence of insulin resistance.”10 However, it 
is interesting to note that the group with insulin resistance 
had an average body mass index of over 31 while those 
without insulin resistance had an average body mass index 
of only 27.10 Furthermore, there was no reporting of blood 
pressure values. Although it is possible that higher levels 
of insulin increased the rate of cardiovascular events in this 
population, it is equally plausible than other factors such as 
hypertension were responsible.
This then begs the question of whether hypertension is 
a byproduct of hyperinsulinemia. Although no unequivocal 
data to answer this question exist, multiple experiments 
in dogs have shown this not to be the case. There were no 
pressor effects noted in normal dogs infused with insulin, 
or in dogs with a 70% reduction in kidney mass on a high 
salt diet.11 Interestingly, chronic hyperinsulinemia actually 
caused a reduction in total peripheral vascular resistance as 
well as arterial pressure.11 This decrease in vascular resistance 
disappeared when the dogs were made obese via a high-fat 
diet.11 This series of experiments suggests that in dogs, 
hyperinsulinemia does not cause hypertension. Whether or 
not this translates into humans remains to be seen. However, 
a cross-sectional relational study found obesity to be an inde-
pendent risk factor for left ventricular hypertrophy, but not 
insulin resistance or fasting insulin levels.12 These data seem 
to suggest that obesity and its complications are responsible 
for cardiovascular risk, not merely high insulin levels.
Although there is a theoretical concern of a mitogenic 
effect of insulin analogs, this concern appears limited to the 
long-acting insulin glargine.13 Glargine appears to be a more 
potent stimulus of DNA synthesis in human osteosarcoma 
cell lines than the native insulin molecule; the rapid-acting 
analogs appear to be equivalent to regular insulin.14 Some 
have postulated that mitogenic potency is related to the half-
life of the receptor–ligand binding complex, which would 
explain why the rapid-acting analogs do not appear to have 
as much theoretical mitogenic effect as the long-acting 
analog glargine.15
Does intensive diabetes therapy 
with insulin improve vascular events?
Recently, there have been several large prospective studies 
examining the relationship between the treatment of hyper-
glycemia and vascular complications. The ﬁ  rst major study 
to associate a decrease in vascular events with glycemic 
control was the United Kingdom Prospective Diabetes Study 
(UKPDS). This prospective observational study included 
4585 type 2 diabetic subjects. It concluded that each 1% 
reduction in mean HbA1c was associated with a risk reduction 
of 21% for deaths related to diabetes, 14% for myocardial 
infarction, and 37% of microvascular complications.16
These patients were followed for another 10 years without 
diabetic treatment manipulation by the researchers. Despite 
the difference in HbA1c disappearing after one year, the group 
intensively treated initially with insulin or sulfonylurea still had 
a 24% risk reduction for microvascular disease, a 15% in risk 
reduction for myocardial infarction, and a 13% reduction for 
death from any cause.17 Because patients initially treated with 
metformin also had risk reductions, the authors of this study 
concluded that this legacy effect was not the result of insulin, 
but rather a possible reduction in advanced glycation end prod-
ucts from the initial intensive treatment of hyperglycemia.18
The Diabetes Control and Complications Trial (DCCT) 
and the subsequent Epidemiology of Diabetes Interven-
tions and Complications (EDIC) illustrated that intensive 
insulin therapy in type 1 diabetic patients reduced the 
major diabetic complications of neuropathy, nephropathy, 
and retinopathy.19 Intensive insulin therapy was associated 
with less cardiovascular disease as evidenced by decreased 
intima-media thickness and lower coronary artery calcium 
accumulation.20 Intensive insulin treatment also decreased 
the risk of any cardiovascular disease by 42% and the risk 
of non-fatal stroke, myocardial infarction, or cardiovascular 
death by 57% in type 1 diabetic subjects.21
Intensive insulin treatment was also shown to be beneﬁ  -
cial to those with the worst vascular disease. Diabetic patients 
who suffered an acute myocardial infarction had an absolute 
reduction in mortality of 11% when treated with intensive 
insulin therapy.22Vascular Health and Risk Management 2009:5 227
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Other studies have been less convincing. The recent 
Action in Diabetes and Vascular Disease (ADVANCE) trial 
was aimed to address the effect of intensive glucose control 
on vascular outcomes in subjects with type 2 diabetes. 
The researchers randomly assigned 11,140 type 2 diabetic 
patients to standard glucose control or intensive glucose 
control using to a HbA1c of 6.5% or less.23 Although the 
ﬁ  rst line drug was a sulfonylurea, 40.5% of subjects in the 
intensive arm and 24.1% of subjects in the standard arm 
ended up on insulin.23 After a median of 5 years of follow-
up, the researchers found that intensive glucose control led 
to a reduction in nephropathy (4.1 versus 5.2%), but had no 
effect on retinopathy, major macrovascular events, or death 
from cardiovascular causes.23
The Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) trial also attempted to address the relationship 
between vascular events and glucose control in patients with 
type 2 diabetes. One distinguishing feature of this trial is that 
all subjects had to have either established cardiovascular 
disease or additional cardiovascular risk factors. Therefore, 
it was aimed for secondary instead of primary preven-
tion of vascular disease. 10,251 subjects were randomly 
assigned to intensive therapy (HbA1c   6%) or standard 
therapy (HbA1c 7.0%–7.9%).24 This portion of the study 
(a blood pressure arm is still ongoing) was discontinued 
after a mean of 3.5 years of follow up due to an increase in 
total mortality (257) in the intensive group as opposed to the 
standard group (203).24 Interestingly, the number of events 
in the primary outcome (non-fatal myocardial infarction, 
non-fatal stroke, or death from cardiovascular cause) was 
actually lower in the intensive group (352) as compared to 
the standard group (371).24 This calls into debate whether 
the increase in deaths was due to vascular complications, 
or if the increase would have panned out had the trial not 
ceased prematurely. Thus far, there has been no concrete 
explanation for the increase in mortality seen in the inten-
sive arm. However, some postulate that hypoglycemia may 
have contributed to the cardiovascular events.25 If so, then 
theoretically, in comparison to regular insulin, the lower 
hypoglycemic rate associated with the rapid-acting analogs 
could provide a cardiovascular beneﬁ  t.26
A third trial, the Veterans Affairs Diabetes Trial, also 
examined the effects of intensive blood glucose control on 
cardiovascular events. The intensive goal in this trial was 
deﬁ  ned by a goal HbA1c of   7.5% and a standard arm goal 
of HbA1c   8.3%, while controlling lipids and blood pres-
sure in both arms.27 This trial was conducted at 20 different 
VA centers with 1791 patients with a mean follow-up of 
6.25 years. In this study, there was no signiﬁ  cant reduction 
in cardiovascular events in the intensive arm.28
Thus, the effect of aggressive control of blood glucose 
on cardiovascular events remains debatable. UKPDS and 
DCCT/EDIC have shown that tight control in younger 
patients in recently diagnosed disease was beneﬁ  cial, whereas 
ADVANCE, ACCORD, and VADT have shown that in 
older patients with long-standing disease the beneﬁ  ts of tight 
glucose control are not as convincing. Diabetes control may 
very well have different effects on different cohorts.
How might insulin reduce vascular 
events?
Insulin’s beneﬁ  cial effects on the vascular system are likely 
due to actions on the endothelium (see Table 1). Insulin has 
been shown to be a potent vasodilator by causing an increased 
production of nitric oxide.29 Insulin induces the expression 
of nitric oxide synthetase, which converts arginine to nitric 
oxide.30 Separate experiments then illustrated that nitric 
oxide levels increase in a dose dependent manner in human 
vein endothelial cells as well as human aortic endothelial 
cells.31,32 These observations were translated in humans when 
researchers infused insulin into normal subjects’ arteries, and 
found that blood ﬂ  ow increases in a dose dependent manner 
with insulin.29
However, in type 2 diabetic as well as non-diabetic obese 
patients, the vasodilatory effect of insulin is blunted.33,34 
Whether this decrease in vasodilation is due to insulin resis-
tance or if insulin resistance is a byproduct of a decrease 
in skeletal muscle perfusion and insulin-mediated glucose 
uptake remains to be seen.
In addition to effects on vascular tone, diabetes also has 
an inﬂ  ammatory component, characterized by endothelial 
dysfunction and elevated adhesion molecules.35 Insulin 
helps to counteract this inﬂ  ammation, by suppressing the 
expression of adhesion molecules, allowing monocytes to 
couple with endothelial cells, releasing monocyte chemoat-
tractant protein-1 (MCP-1). This in turn attracts more mono-
cytes which then intermingle with low-density lipoprotein 
cholesterol, forming foam cells.29 Insulin also reverses the 
increase in the adhesion molecule e-selectin seen in type 2 
diabetic subjects.36
Along with suppressing MCP-1 and e-selectin, insulin 
also suppresses nuclear factor kappa B (NF-kB).37 NF-kB 
is a central ﬁ  gure in inﬂ  ammation, responsible for the pro-
duction of cytokines, enzymes, and adhesion molecules.38 
When human aortic endothelial cells were incubated with 
insulin, intranuclear NF-kB binding activity and MCP-1 Vascular Health and Risk Management 2009:5 228
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mRNA expression were both suppressed.37 This decrease in 
MCP-1 was replicated in vivo in obese subjects, in whom the 
translocation of NF-kB was inhibited by insulin infusion.39 
Insulin also decreases NADPH oxidase, plasma tissue factor, 
and matrix metalloproteinase.29
Insulin has been shown to decrease the inﬂ  ammatory 
marker C-reactive protein in critically ill patients.40 In patients 
suffering from an acute myocardial infarction, insulin has anti-
inﬂ  ammatory and pro-ﬁ  brinolytic effects as evidenced by a 
blunting of the increase in high-sensitivity C-reactive protein, 
serum amyloid A, and plasminogen activator inhibitor-1.41
Are the effects of insulin a class effect?
It is unclear if the effects of insulin are unique to a certain 
formulation or are class effects that extend to the rapid-
acting insulin analogs. Table 1 summarizes the experimental 
evidence of the various formulations of short-acting insulin. 
One type of rapid-acting insulin is lispro (Humalog®, Eli 
Lilly and Company). Lispro is a human insulin analog 
manufactured from Escherichia coli with the amino acids at 
positions 28 and 29 reversed.42 This reversal of lysine and 
proline allows the insulin to be absorbed much faster than 
regular insulin from subcutaneous tissue. Lispro has a peak 
action of 30 to 90 minutes.42 Because of its fast onset, lispro 
is often used as a bolus insulin to address postprandial glu-
cose excursions. Like the other rapid-acting analogs, it can 
be used alone in an insulin pump, or in combination with a 
longer acting insulin formulation. It is marketed by itself as 
well as pre-mixed with lispro protamine, a crystallized form 
of lispro made by combining lispro with protamine sulfate, 
lengthening its duration of action.43 Clinical guidelines and 
algorithms for the use of rapid-acting analogs in diabetic 
patients are beyond the scope of this article.
Table 1 Comparison of rapid-acting insulin analogs with regular insulin
Regular insulin
  Time of onset 30–60 minutes
  Peak action 50–120 minutes
  Duration of action 5–8 hours
  Effects on vascular system
    Improved outcomes in diabetic subjects with decreased
   •  Intima-media  thickness
   •  Cardiovascular  risk
   •   Risk of non-fatal stroke
   •   Risk of myocardial infarction
   •   Risk of cardiovascular death
   •   Mortality post-acute myocardial infarction
  Vasodilation 
  Increases
   •  Nitric  oxide
  Suppresses
   •  Adhesion molecules
   •  E-selectin
   •  MCP-1
   •  Nf-kB
   •  NADPH  oxidase
   •   Plasma tissue factor
   •  Matrix  metalloproteinase
   •  C-reactive  protein
   •  Serum  amyloid  A
   •   Plasminogen activator inhibitor-1
Lispro (Humalog®)
  Time of onset 5–15 minutes
  Peak action 30–90 minutes
  Duration of action 3–5 hours
  Difference from regular insulin
  Produced  from  Escherichia coli
    Lysine and proline at positions 28 and 29 transposed
  Lower  postprandial  glucose
  Effects on vascular system
  Improved  postprandial  blood  ﬂ  ow
Glulisine (Apidra®)
  Time of onset 5–15 minutes
  Peak action 34–91 minutes
  Duration of action 55–149 minutes
  Difference from regular insulin
  Produced  from  Escherichia coli
    Asparaginase at B3 replaced with lysine and lysine at B29 replaced 
with glutamic acid
  Lower  postprandial  glucose
  Effects on vascular system
  Improved  blood  ﬂ  ow postprandially
(Continued)
Table 1 (Continued)
Aspart (Novolog®)
  Time of onset 5–15 minutes
  Peak action 40–50 minutes
  Duration of action 3–5 hours
  Difference from regular insulin
  Produced  from  Saccharomyces cervisiae
    Proline replaced with aspartic acid at B28
  Lower  postprandial  glucose
  Effects on vascular system
    No changes in fasting lipid proﬁ  le, apolipoproteins, ﬁ  brinogen, 
plasminogen activator inhibitor-1, E-selectin, or homocysteine when 
compared to regular insulin.
Note: Time values assume subcutaneous bolus injection.Vascular Health and Risk Management 2009:5 229
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There are some data to show that lispro is beneﬁ  cial to the 
vascular system. Speciﬁ  cally, lispro improves microvascular 
blood ﬂ  ow in postprandial type 1 diabetic patients.44 In this 
study, 20 non-diabetic patients and 20 diabetic patients 
had their skin microvascular blood ﬂ  ow measured by laser 
Doppler ﬂ  ux every 30 minutes after a standardized test meal. 
The researchers found that microvascular blood ﬂ  ow was 
impaired in type 1 diabetic patients given regular insulin, 
but when given insulin lispro, the microvascular blood ﬂ  ow 
improved to mimic the non-diabetic subject. This is thought 
to be due to the treatment of acute hyperglycemia, which 
stimulates the production of free radicals and augments throm-
bin formation.44 Hyperglycemia is also thought to create an 
increase in adhesion molecules and endothelin, while decreas-
ing levels of nitric oxide.45 Because lispro has a faster onset 
of action than regular insulin, it reduces these postprandial 
excursions better, and is more likely to counteract the increase 
in adhesion molecules and decrease in nitric oxide.46
Similar to lispro, glulisine (Apidra®, Sanoﬁ  -Aventis) 
has also been shown to have beneﬁ  cial effects on surro-
gate vascular markers. Glulisine is a rapid-acting insulin 
homologous with regular human insulin save for the amino 
acid asparagine at position B3 replaced with lysine and the 
lysine at position B29 substituted with glutamic acid.47 This 
analog is produced by recombinant DNA using Escherichia 
coli, and it is employed to lower blood glucose in a similar 
fashion as lispro. In a microvascular blood ﬂ  ow study similar 
to the one described above using lispro and regular insulin, 
glulisine was compared to regular insulin in 15 type 2 diabetic 
subjects after a liquid meal challenge. Serial laser Doppler 
ﬂ  uxometry was then performed. Like the results in the lispro 
study, glulisine-reated subjects had higher postrandial insulin 
levels, lower glucose excursions, and higher microvascular 
blood ﬂ  ow.48 Again, without any head to head comparison 
studies, it is impossible to say that the short-acting insulin ana-
logs are equal. Yet, the fact that both glulisine and lispro had 
similar effects in a similarly designed study suggests a class 
effect beneﬁ  t from treating postprandial glucose excursions.
Although a similar study using laser ﬂ  uxometry has not 
been published using aspart (NovoLog®, Novo Nordisk Inc.), 
there have been other studies examining the effect of aspart 
on vascular risk factors. Aspart is similar in composition to 
regular human insulin, save for the substitution of the amino 
acid proline with aspartic acid in position B28.49 It is produced 
using recombinant DNA technology using Saccharomyces 
cerevisiae (baker’s yeast) and is used to treat hyperglycemia 
in a similar fashion as lispro and glulisine. Despite the similar 
function and onset of action, the data on aspart’s effects on the 
vascular system are not as clear as with the other rapid-acting 
analogs. Twenty-one patients with insulin-treated type 2 dia-
betes were given neutral protamine Hagedorn (NPH) insulin 
and pre-prandial regular insulin or aspart for 6 weeks.50 At 
the end of the study, although there was no statistical dif-
ference in hemoglobin A1c (HbA1c), the aspart group had a 
signiﬁ  cantly lower postprandial (90 minutes after a meal) 
average glucose (7.9 mmol/L versus 9.3 mmol/L).50 Despite 
this decrease in glucose excursions, there were no statistical 
differences in markers of vascular risk (fasting lipid proﬁ  le, 
apolipoproteins, ﬁ  brinogen, plasminogen activator inhibi-
tor-1, E-selectin, or homocysteine). However this study has 
several limitations to preclude the conclusion that treating 
postprandial glucose excursions has no effect on vascular 
risk. This study’s conclusion may reﬂ  ect a lack of power, 
brief study duration, or even a difference between the effects 
of distinct insulin analogs on vascular risk.
Does treatment of postprandial 
glucose help?
The rapid-acting insulins’ superiority lies in their ability to 
treat postprandial glucose and excursions. Is such an ability 
clinically relevant? Fortunately, several studies highlight how 
postprandial excursions and high glucose variability affect 
the vascular system. One such study involved type 1 diabetic 
patients who underwent myocardial perfusion studies while 
either on a euglycemic or hyperglycemic hyperinsulinemic 
clamp. The myocardial perfusion reserve was signiﬁ  cantly 
decreased when subjects were hyperglycemic.51
Just as chronic diabetes is associated with inﬂ  amma-
tion, acute hyperglycemia has also been shown to cause 
an increase in proinﬂ  ammatory cytokines such as tumor 
necrosis factor-alpha, interleukin (IL)-6, IL-1 beta, and IL-8, 
which leads to vascular inﬂ  ammation.52 This increase in 
cytokines was counteracted by insulin infusion and a return 
to normoglycemia.52
By mitigating hyperglycemia with a faster onset of action 
than regular insulin, some have argued that rapid-acting 
insulin may have favorable cardiovascular effects.53,54 One 
argument is that using premixed lispro combinations lower 
postprandial glucose better than regular insulin combina-
tions, and therefore may reduce CVD risk.54 When lispro was 
added to bedtime NPH insulin and compared to twice-daily 
NPH in type 2 diabetic subjects, the lispro-treated group 
experienced lower postprandial glucose, lower HbA1c, lower 
triglycerides, low-density lipoprotein cholesterol (LDL), 
and higher high-density lipoprotein cholesterol (HDL).53 
The authors surmised that this favorable milieu might have Vascular Health and Risk Management 2009:5 230
Fordan and Raskin
a positive cardiovascular effect. In addition, a recent study 
was performed comparing the long-acting insulin detemir 
(Levemir®, Novo Nordisk Inc.) to the rapid-acting aspart. It 
found that patients using a prandial bolus of insulin aspart had 
a lower HbA1c than those treated with basal detemir.55 These 
two studies would suggest that the postprandial excursions 
can drive overall blood glucose control, and that by treating 
this variability, vascular events could be mitigated. Reduc-
ing glycemic variability could also lessen glycemic events 
due to fewer episodes of hypoglycemia. A recent study of 
100 type 1 diabetic patients followed for 11 years found a 
strong correlation between glycemic variability and hypo-
glycemic unawares.56 It is possible that using insulin analogs 
could reduce glycemic variability and hypoglycemic epi-
sodes, whereby overall glucose control and vascular events 
are improved. However, this theory can only be answered 
with a prospective long-term study with an extremely large 
sample size using rapid-acting insulin.
On the other hand, speciﬁ  cally targeting postprandial 
glucose may not have a clinically signiﬁ  cant vascular effect. 
The hyperglycemia and its effect after acute myocardial 
infarction on cardiovascular outcomes in patients with 
type 2 diabetes mellitus (HEART2D) attempted to random-
ize 1355 subjects with type 2 diabetes and acute myocardial 
infarction to either pre-meal insulin lispro with basal NPH 
insulin, (with a target 2-hour postprandial blood glucose 
of  135 mg/dL) or basal insulin only (NPH insulin twice 
daily, insulin glargine once daily, or pre-mixed human insulin 
[70% NPH/30% regular] twice daily) targeting fasting.57 
Although both groups ended up with similar HbA1c values 
(7.6%), and the lispro-treated group had statistically fewer 
postprandial excursions, there was no signiﬁ  cant difference in 
cardiovascular events between the two groups and the study 
was stopped for “futility.”58 These data would suggest that 
glycemic variability does not increase cardiovascular events, 
although the sample size of the study was relatively small 
and it experienced a high drop out rate.
Conclusion
In summary, the UKPDS has shown that treating diabetes 
to a goal HbA1c  7% will decrease some vascular events. 
Intensively treating diabetes to  6% is debatable and dif-
ﬁ  cult given present treatment modalities. Individualized 
goals should be designed between physician and patient. In 
meeting these goals, insulin has been shown to be beneﬁ  cial 
by not only by treating hyperglycemia, but also by provid-
ing vasodilatory and anti-inﬂ  ammatory effects. Although 
not proven, these effects likely extend to the rapid-acting 
analogs. With its faster onset of action and lower postprandial 
glucose excursions, rapid-acting insulin appears superior to 
regular insulin, and could possibly reduce vascular events 
further.
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